ホームページ Cell Cycle CDK4/6

CDK4/6

CDK4/6製品

  • All (2)
  • CDK4/6阻害剤 (2)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
E6647New Bireociclib (XZP-3287,CDK4/6-IN-2) CDK4/6 - IN - 2は、特許US20180000819A1、化合物1から抽出された強力なCDK4およびCDK6阻害剤であり、CDK4およびCDK6に対するIC50はそれぞれ2.7 nMおよび16 nMである。
E6678New PRT3645 PRT3645 is a brain-penetrant CDK4/6 inhibitor that exhibits single-digit nanomolar biochemical potency against CDK4/6 and >2,000-fold selectivity against other CDK family members (CDK1, CDK2, and CDK9). PRT3645 exhibits anti-cell proliferation in glioblastoma (GBM) cell lines and in HER2− and HER2+ breast cancer lines (EC50 of < 125 nM), and demonstrates anti-tumor activity and enhances survival in glioblastoma and breast cancer brain metastasis models.
E6647New Bireociclib (XZP-3287,CDK4/6-IN-2) CDK4/6 - IN - 2は、特許US20180000819A1、化合物1から抽出された強力なCDK4およびCDK6阻害剤であり、CDK4およびCDK6に対するIC50はそれぞれ2.7 nMおよび16 nMである。
E6678New PRT3645 PRT3645 is a brain-penetrant CDK4/6 inhibitor that exhibits single-digit nanomolar biochemical potency against CDK4/6 and >2,000-fold selectivity against other CDK family members (CDK1, CDK2, and CDK9). PRT3645 exhibits anti-cell proliferation in glioblastoma (GBM) cell lines and in HER2− and HER2+ breast cancer lines (EC50 of < 125 nM), and demonstrates anti-tumor activity and enhances survival in glioblastoma and breast cancer brain metastasis models.
E6647New Bireociclib (XZP-3287,CDK4/6-IN-2) CDK4/6 - IN - 2は、特許US20180000819A1、化合物1から抽出された強力なCDK4およびCDK6阻害剤であり、CDK4およびCDK6に対するIC50はそれぞれ2.7 nMおよび16 nMである。
E6678New PRT3645 PRT3645 is a brain-penetrant CDK4/6 inhibitor that exhibits single-digit nanomolar biochemical potency against CDK4/6 and >2,000-fold selectivity against other CDK family members (CDK1, CDK2, and CDK9). PRT3645 exhibits anti-cell proliferation in glioblastoma (GBM) cell lines and in HER2− and HER2+ breast cancer lines (EC50 of < 125 nM), and demonstrates anti-tumor activity and enhances survival in glioblastoma and breast cancer brain metastasis models.